The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort.

Mario Maggi, Ravinder Anand-Ivell, Frederick C W Wu, Dirk Vanderschueren, Jos Tournoy, Giulia Rastrelli, Margus Punab, Terence W O'Neill, Daryl B O'Connor, Gyorgy Bartfai, Ilpo T Huhtaniemi, Leen Antonio, Katie Severn, Kee Heng, Richard Ivell, Felipe F Casanueva, Aleksander Giwercman, Jolanta Slowikowska-Hilczer

Journal: Frontiers in endocrinology 2022;13():1016107

PMID: 36425465

Abstract

BACKGROUND

Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation status.

OBJECTIVES

To determine the ability of INSL3 to predict hypogonadism and age-related morbidity using the EMAS cohort of older community-dwelling men.

MATERIALS & METHODS

Circulating INSL3 was assessed in the EMAS cohort and its cross-sectional and longitudinal relationships to hypogonadism, here defined by testosterone (T) <10.5nmol/l, and a range of age-related morbidities determined by correlation and regression analysis.

RESULTS & DISCUSSION

While INSL3 is an accurate measure of primary hypogonadism, secondary and compensated hypogonadism also indicate reduced levels of INSL3, implying that testicular hypogonadism does not improve even when LH levels are increased, and that ageing-related hypogonadism may combine both primary and secondary features. Unadjusted, serum INSL3, like calculated free testosterone (cFT), LH, or the T/LH ratio reflects hypogonadal status and is associated with reduced sexual function, bone mineral density, and physical activity, as well as increased occurrence of hypertension, cardiovascular disease, cancer, and diabetes. Using multiple regression analysis to adjust for a range of hormonal, anthropometric, and lifestyle factors, this relationship is lost for all morbidities, except for reduced bone mineral density, implying that INSL3 and/or its specific receptor, RXFP2, may be causally involved in promoting healthy bone metabolism. Elevated INSL3 also associates with hypertension and cardiovascular disease. When unadjusted, INSL3 in phase 1 of the EMAS study was assessed for its association with morbidity in phase 2 (mean 4.3 years later); INSL3 significantly predicts 7 out of 9 morbidity categories, behaving as well as cFT in this regard. In contrast, total T was predictive in only 3 of the 9 categories.

CONCLUSION

Together with its low within-individual variance, these findings suggest that assessing INSL3 in men could offer important insight into the later development of disease in the elderly.

Copyright © 2022 Ivell, Heng, Severn, Antonio, Bartfai, Casanueva, Huhtaniemi, Giwercman, Maggi, O’Connor, O’Neill, Punab, Rastrelli, Slowikowska-Hilczer, Tournoy, Vanderschueren, Wu and Anand-Ivell.

Address: School of Biosciences, University of Nottingham, Sutton Bonington, United Kingdom.; School of Mathematics, University of Nottingham, Nottingham, United Kingdom.; Department of Chronic Diseases and Metabolism, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.; Department of Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy Medical University, Szeged, Hungary.; Department of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS); CIBER de Fisiopatología Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III, Santiago de Compostela, Spain.; Institute of Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.; Department of Translational Medicine, Lund University, Malmö, Sweden.; Andrology Unit, "Mario Serio" Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.; School of Psychology, University of Leeds, Leeds, United Kingdom.; Centre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.; Andrology Clinic, Tartu University Hospital; and Institute of Clinical Medicine, and Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.; Department of Andrology and Reproductive Endocrinology, Medical University of Łódź, Łódź, Poland.; Department of Geriatrics, University Hospitals Leuven, and Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.; Department of Endocrinology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.